Compare ENVX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | WGS |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Miscellaneous | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | N/A |
| Metric | ENVX | WGS |
|---|---|---|
| Price | $6.93 | $39.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $13.61 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 5.2M | 1.4M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,821,000.00 | N/A |
| Revenue This Year | $30.37 | $29.98 |
| Revenue Next Year | $238.73 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | ★ 37.91 | N/A |
| 52 Week Low | $4.67 | $32.21 |
| 52 Week High | $16.49 | $170.87 |
| Indicator | ENVX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 30.39 |
| Support Level | $6.68 | N/A |
| Resistance Level | $8.66 | $96.34 |
| Average True Range (ATR) | 0.44 | 3.84 |
| MACD | -0.00 | -2.34 |
| Stochastic Oscillator | 61.94 | 18.78 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.